Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the preventable nature of many cancers due to modifiable risk factors and emphasizes the importance of preventive oncology in reducing the global cancer burden; it reports no new clinical results.

This article reviews the use of finasteride for treating benign prostatic hyperplasia and its chemopreventive potential for prostate cancer, but it calls for further discussion on its preventive use in high-risk groups.

This review suggests that finasteride at 1 mg/day reduces PSA levels similarly to 5 mg/day, but differences in prostate dihydrotestosterone levels may affect prostate cancer diagnosis and prevention.

This analysis of the Prostate Cancer Prevention Trial found that finasteride reduces prostate cancer risk by nearly 25% and enhances the PSA test's ability to detect prostate cancer and high-risk diseases.

Finasteride reduces prostate cancer risk but may increase high-grade cancer cases.

This review discusses the development and trials of finasteride for prostate cancer prevention, reporting reduced cancer prevalence but noting concerns about increased high-grade cancer incidence.

This study found no clear evidence that finasteride negatively affects erectile function, though it does cause a reduction in ejaculatory volume and has potential implications for prostate cancer risk.

This review discusses the hormonal influences on prostate carcinogenesis and notes ongoing trials investigating whether finasteride could reduce prostate cancer incidence by inhibiting dihydrotestosterone synthesis, but it reports no new results.

This study suggests that finasteride may be a promising treatment for chronic central serous chorioretinopathy, but larger controlled trials are needed to confirm its efficacy.

This study concluded that five-alpha-reductase inhibitors may reduce prostate cancer risk but could increase the risk of high-grade prostate cancer in men regularly screened for the disease.

This review examined studies on erectile dysfunction and 5 alpha-reductase inhibitors, concluding that these drugs do not significantly cause erectile dysfunction and emphasizing testosterone's importance over dihydrotestosterone in erectile function.

This study observed that men with frontal and moderate vertex baldness between ages 40 and 50 had a higher risk of aggressive prostate cancer, suggesting a potential link between baldness pattern and cancer risk.

This study found that taking 1 mg of finasteride daily for male-pattern hair loss significantly reduces serum PSA levels, suggesting similar PSA adjustment is needed as for higher doses during prostate cancer screening.

Finasteride's link to health issues like male breast cancer, infertility, and prostate cancer needs more research through placebo-controlled trials to confirm.

This study found that dutasteride effectively improved urinary symptoms, reduced acute urinary retention risk, and decreased prostate volume in men with moderate to severe BPH over two years.

In this study, short-term finasteride treatment reduced apoptotic factors caspase-7 and IGFBP-3 in prostate cancer cells but did not significantly affect androgen receptor expression compared to placebo.

This review discusses various prostate cancer prevention strategies and reports no new clinical results; the authors highlight the need for ongoing research in this area.

This review examines the role of steroidal inhibitors in treating prostatic diseases but presents no new clinical results.

This review discusses the use of 5α-reductase inhibitors, particularly finasteride, for treating conditions like benign prostatic hyperplasia, male baldness, and hirsutism, and reports no new clinical results.

This review examines medical literature on postfinasteride syndrome and reports no new results; the authors call for more controlled studies on permanent sexual dysfunction and mood changes linked to 5-alpha-reductase inhibitors.

Finasteride effectively treats enlarged prostate and male baldness, improves symptoms of hirsutism in women, but doesn't work for acne, and may delay prostate cancer progression with few side effects.

This review discusses methods for improving study design and evaluation in sexual health literature and reports no new clinical results; it highlights current methodological issues and the benefits of validated questionnaires.

This article reviews the Clinical Pearls presentation format introduced at the American College of Physicians' 2001 meeting for its effectiveness in applying practical clinical tips, but provides no new empirical results.

This study reported that high cholesterol levels were linked to increased prostate cancer risk, while selenium supplementation affected gene expression, suggesting nutritional and clinical factors might influence prostate cancer risk and biology.

The document concludes that various medications and treatments can have significant, sometimes adverse, effects on health outcomes.

This study found that dutasteride significantly reduces the risk of acute urinary retention and surgical intervention in men with benign prostatic enlargement compared to placebo.

This review discusses the evidence for using oral medications to treat central serous chorioretinopathy, highlighting eplerenone as having the most support despite a lack of robust efficacy across studies.

Finasteride significantly reduces the risk of prostate cancer.

This study concludes that the accuracy of PSA testing for prostate cancer diagnosis is not only maintained but may be increased when used alongside 5-alpha reductase inhibitors like finasteride and dutasteride.